L. López

ORCID: 0009-0003-5014-9954
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Gastric Cancer Management and Outcomes
  • Cancer Genomics and Diagnostics
  • Helicobacter pylori-related gastroenterology studies
  • Gastrointestinal Tumor Research and Treatment
  • Pancreatic and Hepatic Oncology Research
  • Cancer Treatment and Pharmacology
  • Colorectal Cancer Treatments and Studies
  • Microscopic Colitis
  • Gastroesophageal reflux and treatments
  • Bone and Joint Diseases
  • Neuroendocrine Tumor Research Advances
  • Intestinal and Peritoneal Adhesions
  • Catalytic Processes in Materials Science
  • Colorectal Cancer Screening and Detection
  • Biosimilars and Bioanalytical Methods
  • Esophageal and GI Pathology
  • Cancer Immunotherapy and Biomarkers
  • Hepatocellular Carcinoma Treatment and Prognosis
  • HER2/EGFR in Cancer Research
  • Renal cell carcinoma treatment
  • Catalysis and Oxidation Reactions
  • Mesoporous Materials and Catalysis
  • Genetic factors in colorectal cancer

Guardian Angel Homes
2021-2022

Hospital Virgen de la Salud
2006-2021

Complejo Hospitalario de Salamanca
2020

Princess Margaret Cancer Centre
2009

Novel, effective treatments for Helicobacter pylori infection are needed. This study evaluated the efficacy of vonoprazan, a potassium-competitive acid blocker, vs standard treatment on H eradication in United States and Europe.In randomized, controlled, phase 3 trial, treatment-naïve adults with were randomized 1:1:1 to open-label vonoprazan dual therapy (20 mg twice daily; 1 g amoxicillin times daily), or double-blind triple day (vonoprazan 20 lansoprazole 30 mg; g; clarithromycin 500 mg)...

10.1053/j.gastro.2022.05.055 article EN cc-by Gastroenterology 2022-06-06

Treatment with nab-paclitaxel plus gemcitabine increases survival in patients metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety non-selected a real-life setting may provide useful information to support decision-making processes routine practice.Retrospective, multicenter study including cancer, who started first-line between December 2013 June 2015 according clinical practice. In addition describing pattern, overall (OS) progression-free (PFS) were...

10.1186/s12885-018-5101-3 article EN cc-by BMC Cancer 2018-11-29

Objectives: to evaluate the diagnostic yield of endoscopic ultrasonography in loco-regional staging gastric cancer our medium and determine impact this technique on later therapeutic management.Material methods: is a retrospective study carried out patients histologically diagnosed with adenocarcinoma who had been referred for ultrasonographic examination.The results were compared those obtained from surgical samples and/or exploratory laparoscopylaparotomy.We initial decision based...

10.4321/s1130-01082010000700003 article EN publisher-specific-oa Revista Española de Enfermedades Digestivas 2010-07-01

Introduction: Eradication rates with standard PPI-based triple therapy (TT) for Helicobacter pylori infection are falling, primarily due to increasing antimicrobial resistance. Here, we present the efficacy and safety results of a Phase 3 trial (PHALCON-HP; NCT04167670) in US European patients H pylori, investigating novel TT dual (DT) regimens containing vonoprazan, an investigational potassium-competitive acid blocker, vs PPI TT. Methods: Patients (N=1046) aged ≥18 years positive 13C-urea...

10.14309/01.ajg.0000779060.18666.73 article EN The American Journal of Gastroenterology 2021-10-01

El diclofenaco (DFC) es bien conocido como un medicamento antiinflamatorio no esteroideo y su alta producción consumo lo convierten en contaminante emergente. DFC tiende a acumularse sistemas acuáticos induciendo la toxicidad largo de cadena alimenticia. Desarrollando alternativas para eliminación contaminantes emergentes uno los desafíos más grandes química ambiental, esta manera estamos investigación enfocada hidrodecloración (HDC) usando nanoparticulas hiero zerovalente (nZVI) soportadas...

10.19053/uptc.01217488.v1.ne.2024.18360 article ES CIENCIA EN DESARROLLO 2024-11-15

e15126 Background: Capecitabine is widely used in the treatment of advanced colorectal cancer. Continuous low dose chemotherapy has been postulated to have anti-angiogenic effects discrete from its anti-proliferative on tumors (metronomic therapy). Dalteparin and prednisone also implicated inhibiting tumour angiogenesis hypothesized additive benefit chemotherapy. This randomized phase II study examined effect dalteparin with capecitabine metastatic Methods: Patients cancer were either (C)...

10.1200/jco.2009.27.15_suppl.e15126 article EN Journal of Clinical Oncology 2009-05-20

10649 Background: Standard C schedule is 14 days every 3 w (C14). However, data have shown that C7 as effective and significantly less toxic than C14. The objective to evaluate retrospectively the response rate toxicity of single agent or in combination heavily pretreated p with advanced solid tumours. Methods: tumour, age ≤ 75 years, ECOG PS <2 adequate bone marrow, renal hepatic functions were analyzed. received C7: 1250 mg/m 2 /12 h x 7 every-other week. drugs doses adjusted be used 1...

10.1200/jco.2006.24.18_suppl.10649 article EN Journal of Clinical Oncology 2006-06-20

Background: Graft versus host disease is the most frequent complication after allogeneic transplantation of hematopoietic progenitors. Its chronic form usually involves a multisystemic syndrome that reflects complex immune response with varying degrees inflammation, dysregulation and fibrosis, responsible for characteristic clinical manifestations disease. Joint, muscular fascial involvement represents one areas, often unnoticed or poorly evaluated, negatively impacts physical function...

10.1136/annrheumdis-2020-eular.3386 article EN Annals of the Rheumatic Diseases 2020-06-01
Coming Soon ...